BullFrog AI Lands Big Pharma Deal To Crack Depression Drug Targets

Bullfrog AI Holdings (NASDAQ:BFRG) shares are surging on Monday following a commercial agreement with a top-five global pharmaceutical company to identify and prioritize therapeutic targets in major depressive disorder. BFRG Jumps on Top-5 Pharma Deal The agreement covers applying the company’s proprietary bfLEAP platform to identify and prioritize novel drug targets in major depressive disorder (MDD), accelerating the Customer’s drug discovery and clinical development program. Large And Growing Depression Market Opportunity The agreement also provides exclusive access to a target candidate. Stellar Market Research valued the MDD market at more than $8 billion in 2025 and expects it to grow at an average annual rate of nearly 5%, reaching in excess of $11 billion by 2032. The agreement is expected to enhance Bullfrog AI’s capabilities in advancing medicines through its analytical AI/ML platform, bfLEAP. The partnership is a significant step forward for the company, potentially leading to new therapeutic developments in a critical area of healthcare. Bullfrog AI Targets Drug Development Inefficiencies Last week, BullFrog AI introduced bfARENAS, a scenario-based decision engine. The engine aims at improving pharmaceutical portfolio strategy and clinical trial design, as the company looks to address inefficiencies in drug development driven by high uncertainty and failure rates. The company said that the new platform helps biotech and pharmaceutical organizations navigate complex R&D environments, where long timelines, limited capital, and high failure rates remain persistent challenges. Vin Singh, founder and CEO of BullFrog AI, said on Wednesday that many companies still struggle to convert growing volumes of data into consistent and transparent decision-making frameworks. He noted that this often leads to inefficient capital allocation across development programs. BFRG Price Action: Bullfrog AI shares were up 172.48% at $1.38 at the time of publication on Monday, according to Benzinga Pro data. Image via Shutterstock